Frontline T-DM1 in HER2+ Metastatic Breast Cancer

Panelists: Adam M. Brufsky, MD, PhD, University of Pittsburgh; Sara Hurvitz, MD, UCLA;
Joyce A. O'Shaughnessy, MD, US Oncology; Edith A. Perez, MD, Mayo Clinic; Hope S. Rugo, MD, UCSF;
Andrew D. Seidman, MD, MSKCC
Published Online: Friday, June 28, 2013
For High-Definition, Click
Frontline treatment with T-DM1 (ado-trastuzumab emtansine; Kadcyla) is currently being explored for patients with HER2-positive metastatic breast cancer in several phase III trials. These large studies were preceded by successful phase II investigations, including the TDM4450g study.

In this study, T-DM1 was compared to trastuzumab plus docetaxel in 137 women with previously untreated, HER2-positive metastatic breast cancer. Overall, notes Sara Hurvitz, MD, T-DM1 was associated with an improvement in progression-free survival of approximately 5 months. Additionally, there was significantly less toxicity with T-DM1, including over a 50% reduction in grade 3/4 adverse events.

Additionally, the phase III MARIANNE trial is examining T-DM1 plus or minus pertuzumab compared to trastuzumab plus a taxane. This large global trial enrolled 1095 patients nearly a year earlier than expectations, Edith A. Perez, MD, explains. The last patient was enrolled to the trial in May 2012 and early results are expected by 2014, potentially at the ASCO Annual Meeting.

The MARIANNE trial is powered to allow for the comparison of both investigational arms to the control. Additionally, it will allow for a comparison directly between the two investigational arms. The results from this trial could potentially be practice changing, Perez believes.

One of the end results of this trial will be to learn whether T-DM1 with pertuzumab or T-DM1 alone is better than a taxane plus trastuzumab, remarks Andrew D. Seidman, MD. However, it will not provide data on whether these approaches are superior to a taxane plus trastuzumab and pertuzumab, which was explored in the CLEOPATRA trial.

View More From This Discussion
Episode 1 Introduction and Exploration of Fulvestrant in Breast Cancer
Episode 2 Combination of Anastrozole and Fulvestrant in MBC
Episode 3 BOLERO-2 Trial: Everolimus in Metastatic Breast Cancer
Episode 4 Management of mTOR Inhibitor Side Effects in Breast Cancer
Episode 5 EMILIA Trial: T-DM1 in Metastatic Breast Cancer
Episode 6 Frontline T-DM1 in HER2+ Metastatic Breast Cancer
Episode 7 CLEOPATRA Trial: Frontline Pertuzumab for HER2+ MBC
Episode 8 MA.31 Trial: Taxane With Lapatinib or Trastuzumab
Episode 9 Treatment With Eribulin in Metastatic Breast Cancer
Episode 10 Case Study: Treating HER2-Positive MBC, Part I
Episode 11 Case Study: Treating HER2-Positive MBC, Part II
Episode 12 Paclitaxel With Pertuzumab Plus Trastuzumab in MBC
Episode 13 Case Study: Treating HR+ and HER2- Breast Cancer
Episode 14 Managing Bone Health in Metastatic Breast Cancer
Episode 15 Surgical Removal of Primary Tumors in Stage IV MBC
Episode 16 Case Study: Metastatic Triple-Negative Breast Cancer
Episode 17 Personalized Medicine in Triple-Negative Breast Cancer
Episode 18 Conclusion and Final Thoughts on Managing Breast Cancer
Expert Panelists
Dr Adam Brufsky

Adam M. Brufsky, MD, PhD

Moderator
Professor of Medicine, University of Pittsburgh
Medical Director of the Women’s Cancer Center
at Magee-Womens Hospital of UPMC
and the University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania
 
 

Sara Hurvitz, MD

Assistant Professor & Director,
Hematology/Oncology Breast Cancer Program, UCLA's Jonsson Comprehensive Cancer Center, Los Angeles, California

Joyce A. O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology, PA/US Oncology,
Dallas, Texas
 

Edith A. Perez, MD

Deputy Director of the Mayo Clinic Cancer Center, Director of the Breast Cancer Translational Genomics Program and the Breast Program at Mayo Clinic,
Jacksonville, Florida

Hope S. Rugo, MD

Professor of Medicine and Director of the Breast Oncology, Clinical Trials, and Education Program, University of California San Francisco Comprehensive Cancer Center, San Francisco, California
 

Andrew D. Seidman, MD

Professor of Medicine, Weill Cornell Cancer Center, Attending Physician at Memorial Sloan Kettering Cancer Center,
New York, New York
Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer CongressĀ®
Community Practice Connections: 13th Annual International Congress on the Future of Breast CancerĀ®
Highlights From the 13th Annual International Congress on the Future of Breast CancerĀ®
The content contained in this video is for general information purposes only. The viewer is encouraged to confirm the information presented with other sources. OncLiveTV Peer Exchange makes no representations or warranties of any kind about the completeness, accuracy, timeliness, reliability, or suitability of any of the information, including content or advertisements, contained in this video and expressly disclaims liability for any errors and omissions that may be presented in this video. OncLiveTV Peer Exchange reserves the right to alter or correct any error or omission in the information it provides in this video, without any obligations. OncLiveTV Peer Exchange further disclaims any and all liability for any direct, indirect, consequential, special, exemplary, or other damages arising from the use or misuse of any material or information presented in this video. The views expressed in this video are those of the panelists and do not necessarily reflect the opinion or policy of OncLiveTV Peer Exchange.
 
More Reading
$auto_registration$